• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic beta-blockade.

作者信息

Uusitalo A, Keyriläinen O, Härkönen R, Rautio P, Rehnqvist N, Engvall J, Rosenqvist U, Nyberg G, Aberg A, Ulvenstam G

机构信息

Department of Clinical Physiology, Tampere University Central Hospital, Finland.

出版信息

Acta Med Scand. 1988;223(3):219-25. doi: 10.1111/j.0954-6820.1988.tb15790.x.

DOI:10.1111/j.0954-6820.1988.tb15790.x
PMID:2895564
Abstract

The anti-anginal effect of a controlled-release (Durules) formulation of isosorbide-5-mononitrate (5-ISMN) 60 mg, Imdur, once daily was evaluated in a randomised double-blind, placebo-controlled, crossover study with a placebo run-in period. Each period lasted for 2 weeks. A total of 70 patients (58 men and 12 women) with stable exertional angina pectoris on beta-blockade, mean age 59 years (range 39-71), were included. Exercise testing was performed on a bicycle ergometer 3 hours after the dose at the end of each period. Anginal attacks and intake of sublingual nitroglycerin tablets were noted. Imdur in combination with a beta-blocker significantly increased the total exercise capacity, the time and total work until the onset of chest pain and at 1 mm ST-depression compared with beta-blockade alone. The attack rate and the nitroglycerin consumption were significantly decreased. Headache was the only significant side-effect. In conclusion, the addition of Imdur once daily to beta-blockade significantly increased the anti-anginal effect.

摘要

相似文献

1
Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic beta-blockade.
Acta Med Scand. 1988;223(3):219-25. doi: 10.1111/j.0954-6820.1988.tb15790.x.
2
Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving beta-blockers.
Drugs. 1987;33 Suppl 4:111-7. doi: 10.2165/00003495-198700334-00020.
3
Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris.
J Cardiovasc Pharmacol. 1989 Sep;14(3):358-63. doi: 10.1097/00005344-198909000-00002.
4
The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study.单硝酸异山梨酯(5-ISMN)缓释片对劳力型心绞痛患者运动耐量的影响。一项安慰剂对照研究。
Eur Heart J. 1986 Oct;7(10):835-42. doi: 10.1093/oxfordjournals.eurheartj.a061969.
5
Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.60毫克控释单硝酸异山梨酯每日一次与每日两次给药治疗稳定型心绞痛。一项随机、双盲、交叉研究。瑞典多中心研究小组。
Eur Heart J. 1994 Jan;15(1):108-13. doi: 10.1093/oxfordjournals.eurheartj.a060361.
6
Clinical experience with Imdur in angina pectoris. A review.
Eur J Clin Pharmacol. 1990;38 Suppl 1:S65-8. doi: 10.1007/BF01417567.
7
Evaluation of the antianginal effect of isosorbide-5-mononitrate in patients with chronic stable angina pectoris.5-单硝酸异山梨酯对慢性稳定性心绞痛患者抗心绞痛作用的评估。
Cardiology. 1991;79 Suppl 2:27-30. doi: 10.1159/000174921.
8
Abrupt withdrawal of isosorbide 5-mononitrate (Imdur) after long term treatment in stable angina pectoris. A preliminary report.
Drugs. 1987;33 Suppl 4:118-21. doi: 10.2165/00003495-198700334-00021.
9
Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris.在稳定型心绞痛患者长期使用单硝酸异山梨酯(如依姆多)治疗后突然停药的情况。
Eur Heart J. 1988 Dec;9(12):1339-47. doi: 10.1093/oxfordjournals.eurheartj.a062452.
10
Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.控释和常规5-单硝酸异山梨酯在稳定型心绞痛中的抗缺血和抗心绞痛作用。
Zhonghua Yi Xue Za Zhi (Taipei). 1998 Oct;61(10):577-83.

引用本文的文献

1
Combination and triple therapy in patients with stable angina pectoris not adequately controlled by optimal β-blocker therapy.在稳定型心绞痛患者中,联合治疗和三联疗法对经最佳β受体阻滞剂治疗后控制不佳的情况。
Neth Heart J. 2002 Nov;10(11):455-461.
2
Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.单硝酸异山梨酯:稳定性心绞痛缓释制剂(依姆多)综述
Drugs. 1999 Feb;57(2):261-77. doi: 10.2165/00003495-199957020-00016.
3
North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management angina. North of England Stable Angina Guideline Development Group.
英格兰北部循证指南制定项目:初级保健管理心绞痛循证指南概要版。英格兰北部稳定性心绞痛指南制定小组。
BMJ. 1996 Mar 30;312(7034):827-32.
4
Clinical experience with Imdur in angina pectoris. A review.
Eur J Clin Pharmacol. 1990;38 Suppl 1:S65-8. doi: 10.1007/BF01417567.
5
Prophylactic nitrate therapy in angina pectoris--is there an optimal treatment regimen?心绞痛的预防性硝酸盐治疗——是否存在最佳治疗方案?
Br J Clin Pharmacol. 1992;34 Suppl 1(Suppl 1):19S-23S. doi: 10.1111/j.1365-2125.1992.tb04144.x.